NL-OMON31801撤回2 期
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritis - Extension study ACZ885 in RA patients
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- ovartis
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients (male and non-pregnant, non-lactating females) who completed the core CACZ885A2204, CACZ885A2206, or CACZ885A2207 study without serious or severe drug-related adverse effects may enter the extension study upon signing informed consent. A patient is defined as completing the study if he/she completed the core CACZ885A2204 study up to and including visit 18 (Week 30), or the core CACZ885A2206 study up to and including visit 7 (Day 43 / Week 6), or the core CACZ885A2207 study up to and including visit 7 (Day 85 / Week 12).
排除标准
- •Patients for whom continued treatment in the extension is not considered appropriate by the treating physician. Patients who were non-compliant or who demonstrated a major protocol violation in the core study. Patients who did not complete / discontinued from the core study. Patients with drug related serious adverse events or severe adverse events.
研究者
相似试验
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid arthritis - NDMedDRA version: 6.1Level: PTClassification code 10039073rheumatoid arthritisEUCTR2007-001665-15-ITOVARTIS FARMA179
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-001665-15-BEovartis Pharma Services AG179
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisRheumatoid ArthritisEUCTR2007-001665-15-DEovartis Pharma Services AG179
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-001665-15-NLovartis Pharma Services AG179
已完成
2 期
An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult and adolescent male patients with Tourette Syndrome (TS).Neurological - Other neurological disordersTourette syndromeACTRN12621000319875oema Pharma Australia Pty Ltd15